Pharmaceutical companies in talks with NICE about access to Alzheimer’s drugs Drug manufacturers Lilly and Eisai are in discussion with the National Institute for Health and Care Excellence to appeal the regulator’s rejection of the use of donanemab and lecanemab on the NHS for the third time in June 2025.…
Patient death prompts concerns about clozapine and smoking cessation awareness A patient died in October 2025 from fatal clozapine toxicity after he suddenly stopped smoking.…
Post-finasteride syndrome: pharmacists must lead the conversation on patient safety We would not accept a tooth-whitening procedure that carried a risk of suicide, persistent sexual dysfunction and irreversible neurological harm. Why is it being accepted with finasteride?…
Health news round-up: coffee, ADHD prescribing, and GLP-1s and hair loss The Pharmaceutical Journal’s weekly summary of the important developments in pharmacy and health news you may have missed.…
People with MS in England to be given fampridine as patent expires Fampridine, taken twice daily, improves nerve signalling and walking speed in some patients with multiple sclerosis.…
Pharmacist Support counselling sessions increase by more than half in 2025 Pharmacist Support’s latest impact report also revealed that referrals to counselling for pharmacists increased by nearly one-third in 2025.…
Health news round-up: vaccination, testosterone and neighbourhood health The Pharmaceutical Journal’s weekly summary of the important developments in pharmacy and health news you may have missed.…
Stopping antipsychotics in patients with dementia reduces risk of fracture and delirium The study’s lead author said the “findings provide reassurance” that stopping long-term antipsychotic treatment when no longer needed prevents harms.…
ADHD medicines prescriptions rose again in 2025 More than 991,000 items of lisdexamfetamine were prescribed in NHS primary care in 2025, which is a 36% increase compared with 2024, according to Care Quality Commission data.…
‘Stark lack of government response’ on valproate redress, patient safety commissioner says In her annual report for 2025/2026, Henrietta Hughes said the government was “yet to announce a redress scheme or a timeline for providing a substantive response to the recommendations” made in her previous report on patients harmed by sodium valproate.…
